Volume 90, Issue 1
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



Between 2000 and 2010, Médecins Sans Frontières diagnosed and treated 4,831 patients with visceral leishmaniasis (VL) in the Pokot region straddling the border between Uganda and Kenya. A retrospective analysis of routinely collected clinical data showed no marked seasonal or annual fluctuations. Males between 5 and 14 years of age were the most affected group. Marked splenomegaly and anemia were striking features. An rK39 antigen-based rapid diagnostic test was evaluated and found sufficiently accurate to replace the direct agglutination test and spleen aspiration as the first-line diagnostic procedure. The case-fatality rate with sodium stibogluconate as first-line treatment was low. The VL relapses were rare and often diagnosed more than 6 months post-treatment. Post-kala-azar dermal leishmaniasis was rare but likely to be underdiagnosed. The epidemiological and clinical features of VL in the Pokot area differed markedly from VL in Sudan, the main endemic focus in Africa.

[open-access] This is an Open Access article distributed under the terms of the American Society of Tropical Medicine and Hygiene's Re-use License which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. World Health Organization, 2010. Control of the Leishmaniases. Report of a meeting of the WHO Expert Committee on Control of Leishmaniases, Geneva, 22–26 March 2010. WHO Technical Report Series; no. 949. [Google Scholar]
  2. Elnaiem DA, , 2011. Ecology and control of the sand fly vectors of Leishmania donovani in East Africa, with special emphasis on Phlebotomus orientalis . J Vector Ecol 36: S23S31.[Crossref] [Google Scholar]
  3. Gebre-Michael T, Malone JB, Balkew M, Ali A, Berhe N, Hailu A, Herzi AA, , 2004. Mapping the potential distribution of Phlebotomus martini and P. orientalis (Diptera: Psychodidae), vectors of kala-azar in East Africa by use of geographic information systems. Acta Trop 90: 7386.[Crossref] [Google Scholar]
  4. Jamjoom MB, Ashford RW, Bates PA, Chance ML, Kemp SJ, Watts PC, Noyes HA, , 2004. Leishmania donovani is the only cause of visceral leishmaniasis in East Africa; previous descriptions of L. infantum and “L. archibaldi” from this region are a consequence of convergent evolution in the isoenzyme data. Parasitology 129: 399409.[Crossref] [Google Scholar]
  5. Fendall NR, , 1961. The spread of kala-azar in Kenya. East Afr Med J 38: 417419. [Google Scholar]
  6. Fendall NR, , 1950. Kala-azar in the Kitui Reserve. East Afr Med J 27: 291296. [Google Scholar]
  7. Fendall NR, McKinnon JA, , 1956. Kala-azar in the Baringo District of Kenya; progress report. J Trop Med Hyg 59: 208212. [Google Scholar]
  8. Mutero CM, Mutinga MJ, Ngindu AM, Kenya PR, Amimo FA, , 1992. Visceral leishmaniasis and malaria prevalence in West Pokot District, Kenya. East Afr Med J 69: 38. [Google Scholar]
  9. Wykoff DE, Barnley GR, Winn MM, , 1969. Studies on kala-azar in Uganda–entomological observations. East Afr Med J 46: 204207. [Google Scholar]
  10. Kager PA, Rees PH, , 1983. Splenic aspiration. Review of the literature. Trop Geogr Med 35: 111124. [Google Scholar]
  11. Mueller Y, Nguimfack A, Cavailler P, Couffignal S, Rwakimari JB, Loutan L, Chappuis F, , 2008. Safety and effectiveness of amphotericin B deoxycholate for the treatment of visceral leishmaniasis in Uganda. Ann Trop Med Parasitol 102: 1119.[Crossref] [Google Scholar]
  12. Mueller Y, Mbulamberi DB, Odermatt P, Hoffmann A, Loutan L, Chappuis F, , 2009. Risk factors for in-hospital mortality of visceral leishmaniasis patients in eastern Uganda. Trop Med Int Health 14: 910917.[Crossref] [Google Scholar]
  13. Chappuis F, Mueller Y, Nguimfack A, Rwakimari JB, Couffignal S, Boelaert M, Cavailler P, Loutan L, Piola P, , 2005. Diagnostic accuracy of two rK39 antigen-based dipsticks and the formol gel test for rapid diagnosis of visceral leishmaniasis in northeastern Uganda. J Clin Microbiol 43: 59735977.[Crossref] [Google Scholar]
  14. Cunningham J, Hasker E, Das P, el Safi S, Goto H, Mondal D, Mbuchi M, Mukhtar M, Rabello A, Rijal S, Sundar S, Wasunna M, Adams E, Menten J, Peeling R, Boelaert M, , 2012. A global comparative evaluation of commercial immunochromatographic rapid diagnostic tests for visceral leishmaniasis. Clin Infect Dis 55: 13121319.[Crossref] [Google Scholar]
  15. Chappuis F, Rijal S, Soto A, Menten J, Boelaert M, , 2006. A meta-analysis of the diagnostic performance of the direct agglutination test and rK39 dipstick for visceral leishmaniasis. BMJ 333: 723.[Crossref] [Google Scholar]
  16. Bern C, Adler-Moore J, Berenguer J, Boelaert M, den Boer M, Davidson RN, Figueras C, Gradoni L, Kafetzis DA, Ritmeijer K, Royce C, Russo R, Sundar S, Alvar J, , 2006. Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clin Infect Dis 43: 917924.[Crossref] [Google Scholar]
  17. Seaman J, Boer C, Wilkinson R, de Jong J, de Wilde E, Sondorp E, Davidson R, , 1995. Liposomal amphotericin B (AmBisome) in the treatment of complicated kala-azar under field conditions. Clin Infect Dis 21: 188193.[Crossref] [Google Scholar]
  18. Mueller M, Ritmeijer K, Balasegaram M, Koummuki Y, Santana MR, Davidson R, , 2007. Unresponsiveness to AmBisome in some Sudanese patients with kala-azar. Trans R Soc Trop Med Hyg 101: 1924.[Crossref] [Google Scholar]
  19. Ritmeijer K, Davidson RN, , 2003. Royal Society of Tropical Medicine and Hygiene joint meeting with Medecins Sans Frontieres at Manson House, London, 20 March 2003: field research in humanitarian medical programmes. Medecins Sans Frontieres interventions against kala-azar in the Sudan, 1989–2003. Trans R Soc Trop Med Hyg 97: 609613.[Crossref] [Google Scholar]
  20. Veeken H, Ritmeijer K, Seaman J, Davidson R, , 2000. A randomized comparison of branded sodium stibogluconate and generic sodium stibogluconate for the treatment of visceral leishmaniasis under field conditions in Sudan. Trop Med Int Health 5: 312317.[Crossref] [Google Scholar]
  21. Musa AM, Younis B, Fadlalla A, Royce C, Balasegaram M, Wasunna M, Hailu A, Edwards T, Omollo R, Mudawi M, Kokwaro G, El-Hassan A, Khalil E, , 2010. Paromomycin for the treatment of visceral leishmaniasis in Sudan: a randomized, open-label, dose-finding study. PLoS Negl Trop Dis 4: e855.[Crossref] [Google Scholar]
  22. Zijlstra EE, Khalil EA, Kager PA, El-Hassan AM, , 2000. Post-kala-azar dermal leishmaniasis in the Sudan: clinical presentation and differential diagnosis. Br J Dermatol 143: 136143.[Crossref] [Google Scholar]
  23. Musa A, Khalil E, Hailu A, Olobo J, Balasegaram M, Omollo R, Edwards T, Rashid J, Mbui J, Musa B, Abuzaid AA, Ahmed O, Fadlalla A, El-Hassan A, Mueller M, Mucee G, Njoroge S, Manduku V, Mutuma G, Apadet L, Lodenyo H, Mutea D, Kirigi G, Yifru S, Mengistu G, Hurissa Z, Hailu W, Weldegebreal T, Tafes H, Mekonnen Y, Makonnen E, Ndegwa S, Sagaki P, Kimutai R, Kesusu J, Owiti R, Ellis S, Wasunna M, , 2012. Sodium stibogluconate (SSG) and paromomycin combination compared to SSG for visceral leishmaniasis in East Africa: a randomized controlled trial. PLoS Negl Trop Dis 6: e1674.[Crossref] [Google Scholar]

Data & Media loading...

  • Received : 21 Mar 2013
  • Accepted : 06 Oct 2013
  • Published online : 08 Jan 2014

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error